Head-To-Head Review: Gyre Therapeutics (NASDAQ:GYRE) versus Nutriband (NASDAQ:NTRB)

Nutriband (NASDAQ:NTRB) and Gyre Therapeutics (NASDAQ:GYRE) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and profitability.

Analyst Recommendations

This is a summary of current ratings for Nutriband and Gyre Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nutriband	1	1	0	0	1.50
Gyre Therapeutics	2	0	1	0	1.67

Gyre Therapeutics has a consensus target price of $16.00, suggesting a potential upside of 133.24%. Given Gyre Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Gyre Therapeutics is more favorable than Nutriband.

Institutional & Insider Ownership

19.7% of Nutriband shares are owned by institutional investors. Comparatively, 24.0% of Gyre Therapeutics shares are owned by institutional investors. 52.2% of Nutriband shares are owned by insiders. Comparatively, 9.5% of Gyre Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Nutriband and Gyre Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nutriband	-430.35%	-103.36%	-91.38%
Gyre Therapeutics	-15.47%	-6.57%	-5.35%

Earnings & Valuation

This table compares Nutriband and Gyre Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nutriband	$2.04 million	35.59	-$8.23 million	($0.53)	-11.26
Gyre Therapeutics	$116.59 million	6.56	$5.03 million	($0.21)	-32.67

Gyre Therapeutics has higher revenue and earnings than Nutriband. Gyre Therapeutics is trading at a lower price-to-earnings ratio than Nutriband, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Nutriband has a beta of 2.03, suggesting that its stock price is 103% more volatile than the S&P 500. Comparatively, Gyre Therapeutics has a beta of 1.92, suggesting that its stock price is 92% more volatile than the S&P 500.

Summary

Gyre Therapeutics beats Nutriband on 10 of the 14 factors compared between the two stocks.

About Nutriband

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

About Gyre Therapeutics

Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.